Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?

Charles River Laboratories (CRL) is scheduled to report its Q2 2025 earnings on August 6, with consensus estimates projecting a 10.7% year-over-year decline in EPS to $2.50 and a 4.2% revenue decrease to $982.87 million. Despite these anticipated declines, Zacks's proprietary Earnings ESP model, indicating a positive 0.11%, combined with a Zacks Rank #3, strongly suggests CRL is poised to beat its consensus EPS estimate. This prediction is further supported by the company's consistent record of surpassing EPS expectations in the past four quarters, implying a potential positive near-term stock price reaction.

Analysis

Charles River Laboratories (CRL) presents a mixed but potentially opportunistic profile ahead of its June 2025 quarterly report. The consensus outlook is bearish, forecasting a year-over-year revenue decline of 4.2% to $982.87 million and an earnings per share (EPS) drop of 10.7% to $2.50. Despite these lowered expectations, several proprietary indicators suggest a high probability of a positive EPS surprise. The company's Zacks Earnings ESP (Expected Surprise Prediction) is a positive 0.11%, driven by recent upward analyst revisions, which, when combined with its Zacks Rank #3 (Hold), has historically indicated an earnings beat nearly 70% of the time. This statistical likelihood is reinforced by CRL's strong track record, having surpassed consensus EPS estimates in each of the last four quarters, including a notable +13.59% surprise in the prior quarter. While the setup points towards a potential near-term positive stock reaction post-earnings, the underlying narrative of fundamental contraction remains a key concern. The sustainability of any price appreciation will heavily depend on management's business commentary and forward guidance provided during the August 6th earnings call.

Key Decisions for Investors

• Given the combination of a positive Earnings ESP and a strong history of earnings surprises, tactical investors may consider establishing a bullish position ahead of the August 6th report to capitalize on a potential beat relative to lowered expectations.
• Long-term investors should prioritize management's guidance on the earnings call over the headline EPS number, as the core issue remains the forecasted year-over-year decline in both revenue and earnings.
• It is crucial to monitor revenue figures and forward-looking statements closely, as a weaker-than-expected top-line result or cautious guidance could negate the positive impact of an EPS beat and pressure the stock.